Robert A. Hodgson

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 407 citations

Glucose Homeostasis, Bace1 Inhibitor Verubecestat, Enzyme 1 +20

The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles

Geoffrey B. Varty, Mariagrazia Grilli, A Forlani et al. · Psychopharmacology · 2005 · 166 citations

Anxiolytic-like Effects, Pain Medicine, Medicine +11

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease

Jack D. Scott, Sarah W. Li, Andrew P. J. Brunskill et al. · Journal of Medicinal Chemistry · 2016 · 161 citations · Full text

Neurochemical Biomarkers, Peptide Science, Enzyme 1 +19

Regional Study of Jointing in Comb Ridge-Navajo Mountain Area, Arizona and Utah

Robert A. Hodgson · AAPG Bulletin · 1961 · 149 citations

Facies Analysis, Engineering, Structural Geology +12

Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression

Robert A. Hodgson, Rosalia Bertorelli, Geoffrey B. Varty et al. · Journal of Pharmacology and Experimental Therapeutics · 2009 · 146 citations